Skip to main content

Table 7 The list of related studies

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Years Authors Trial or research Research design Primary endpoint RT/CRT Vs. RT/CRT + cetuximab P value Cancer
2006 Bonner JA et al. NCT00004227 RT(n = 213) Vs. RT + cetuximab(n = 211) LR control (2 yr) 41% Vs. 50% 0.005 HNSCC
2014 K. Kian Ang et al. RTOG 0522 Phase III CRT(n = 444) Vs. CRT + cetuximab(n = 447) PFS (3 yr) 61.2% Vs. 58.9% 0.76 HNSCC
2016 Xin Wu et al. A retrospective matched case–control study TPF + CRT(n = 56) Vs. TPF + RT + cetuximab(n = 56) OS (5 yr) 79.3% Vs. 79.5% 0.797 NPC
2015 T. Xu et al. NCT01614938 Phase II CRT(n = 23) Vs. RT + cetuximab(n = 21) DFS (3 yr) 78.3% Vs. 85.7% 0.547 NPC